National Center for Research Resources

Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health

Retrieved on: 
Thursday, November 9, 2023
Knowledge, CCHP, Research, Practitioner, National Center for Health Statistics, CKM, University of Colorado School of Medicine, National Center for Research Resources, Health, Obesity, Physician, Congress, American Heart Association, MD, Certification, Diabetes, Type 2 diabetes, University of Colorado Hospital, Medicine, Hypertension, Annual, Systemic, Kidney disease, University, CMHC, AHA, Pharmacist, Nursing, Dyslipidemia, Atherosclerosis, Pharmaceutical industry

Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now have the opportunity to sit for the Certified Cardiometabolic Health Professional (CCHP) examination.

Key Points: 
  • Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now have the opportunity to sit for the Certified Cardiometabolic Health Professional (CCHP) examination.
  • Regarding the certification announcement, Dr. Eckel said, "I cannot overstate the tremendous implications of having a dedicated certification on the entire field of cardiometabolic health.
  • The Foundations of Cardiometabolic Health Certificate Course is currently open for enrollment to physicians, nurses, residents, fellows, and any other health professional interested in furthering their knowledge in the core principles of cardiometabolic health.
  • Cardiometabolic Health Congress (CMHC) is a single point of access for breakthrough research, comprehensive education, and practical clinical strategies surrounding cardiometabolic health.

EQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Retrieved on: 
Friday, April 28, 2023
National Center for Complementary and Integrative Health, Sclerosis, Inauguration, Vincent, Cleveland Clinic, Short course immune induction therapy, University, Biogen, Biotechnology, National Center for Research Resources, National Multiple Sclerosis Society, American Academy, Multiple sclerosis, Innovation Unit, Bangladesh Technical Education Board, Cleveland, Advisory Council, Presidential Advisory Council on HIV/AIDS, Council, Neurology, Knowledge, Faculty, Case Western Reserve University School of Medicine, American Academy of Neurology, History of Cleveland Clinic, Holding company, Pharmaceutical industry, Management, Research

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Key Points: 
  • Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
  • Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
  • The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023.
  • “We are very grateful to have Rick join us,” stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic.

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Retrieved on: 
Thursday, April 27, 2023
National Center for Advancing Translational Sciences, Sclerosis, Inauguration, Vincent, Cleveland Clinic, Short course immune induction therapy, University, Biogen, National Center for Research Resources, National Multiple Sclerosis Society, American Academy, Multiple sclerosis, Innovation Unit, Bangladesh Technical Education Board, Cleveland, Advisory Council, Presidential Advisory Council on HIV/AIDS, Council, Neurology, Knowledge, Faculty, Case Western Reserve University School of Medicine, American Academy of Neurology, History of Cleveland Clinic, Pharmaceutical industry, Management, Research

NEW YORK, April 27, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Richard Rudick, M.D., a thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry, to its board of directors, effective April 26, 2023. The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023.

Key Points: 
  • The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023.
  • "We are very grateful to have Rick join us," stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic.
  • He has published extensively and been an active participant and leader in developing the current treatment landscape for multiple sclerosis.
  • "On behalf of the entire Board of Directors, I would like to thank Vincent for his dedication to Immunic and his thoughtful guidance over the past seven years.

FUJIFILM Wako Chemicals U.S.A. Commercializes CEPT Cocktail for Research-Use iPSC Applications

Retrieved on: 
Thursday, April 20, 2023
National Center for Research Resources, Polyamine, DNA, IPSC, DSM-IV codes, Workflow, Culture, Cell, Gene editing, Fujifilm, NIH, NCATS, Hope, CEPT, National Center for Advancing Translational Sciences, Bangladesh Technical Education Board, Cryopreservation, DNA repair, Tissue engineering, Drug discovery, Toxicology, DMSO, Mobile phone, Pharmaceutical industry, Emricasan, Corporation

CEPT Cocktail is intended for commercial research-use of iPSC applications including disease modeling, organoid generation, drug discovery, toxicology, and pharmacological studies.

Key Points: 
  • CEPT Cocktail is intended for commercial research-use of iPSC applications including disease modeling, organoid generation, drug discovery, toxicology, and pharmacological studies.
  • Compared to other commercially available reagents, FUJIFILM Wako Chemicals U.S.A., Corporation’s CEPT Cocktail consists of a mixture of all the components, providing comprehensive cell protection and viability.
  • Under a license granted from the National Center for Advancing Translational Sciences (NCATS) and NIH, Fujifilm commercializes CEPT cocktail as a research-use-only, ready-to-use DMSO solution.
  • “As part of a robust offering of iPSC technologies and cell culture media solutions, FUJIFILM Wako Chemicals U.S.A., Corporation is proud to commercialize the CEPT Cocktail with the hope of further advancing the role of iPSCs and their limitless potential in translational medicine,” said Toshihiro Hiramatsu, president, FUJIFILM Wako Chemicals, U.S.A., Corporation.

Heart Muscle Tissue Chips Among Life Science Investigations Launching to ISS on SpaceX CRS-27

Retrieved on: 
Wednesday, March 8, 2023
Redwire, SpaceX, Boeing, ISS National Lab, Stanford University, BFF, CRS, Meniscus, Research, Bangladesh Technical Education Board, 3D bioprinting, Crystallization, Biotechnology, International Space Station, SPACE, Heart, Tissue, Partnership, Kennedy Space Center Launch Complex 39A, Kennedy Space Center, Patient, Johns Hopkins University, Commercial Resupply Services, Skeletal muscle, ISS, National Center for Advancing Translational Sciences, Medicine, Bristol Myers Squibb, Temperature, Knowledge, Scientific research on the International Space Station, United States Commercial Service, MassChallenge, NIH, National Center for Research Resources, Pharmaceutical industry, Communications satellite, 3D printing, Science

These projects, sponsored by the ISS National Laboratory, will study microgravity's effects on engineered heart muscle tissue, and results could lead to new treatments for heart disease.

Key Points: 
  • These projects, sponsored by the ISS National Laboratory, will study microgravity's effects on engineered heart muscle tissue, and results could lead to new treatments for heart disease.
  • These projects were funded through the Tissue Chips in Space initiative , a multiyear collaboration between the ISS National Lab and NIH's National Center for Advancing Translational Sciences.
  • Muscles, including the heart, can weaken in microgravity, so heart muscle tissue chips in space could be used to model heart disease and screen potential new drugs.
  • These are only a few of the investigations sponsored by the ISS National Lab that are launching on this mission.

Dr. Rohit Varma Shares Eye-Disease Research at the 2nd Mexico-United States Symposium on Vision Health

Retrieved on: 
Friday, January 27, 2023
Science, Public Policy, Government, Research, White House, Federal Government, Optical, Health, Diabetes, Clinical Trials, International Partnership on Avian and Pandemic Influenza, Paratriathlon, National Institutes of Health, Symposium, Eye disease, National Eye Institute, NEI, Bangladesh Technical Education Board, NIH, IMO, HHS, Impact, Eye Health UK, University, Visual impairment, Diplomatic mission, Public health, United States Department of Health and Human Services, Eye, Partnership, Leonard M. Miller School of Medicine, Multimedia, National Center for Research Resources, Symposium (Plato), Prevalence, National Institute on Minority Health and Health Disparities, Pharmaceutical industry, Ophthalmology

Symposium on Vision Health .

Key Points: 
  • Symposium on Vision Health .
  • View the full release here: https://www.businesswire.com/news/home/20230127005421/en/
    An internationally acclaimed clinician and epidemiologist, Dr. Rohit Varma is the world’s foremost expert on eye disease in Latinos.
  • (Photo: Business Wire)
    The Symposium is a partnership between the Government of Mexico and the United States Department of Health and Human Services (HHS), National Institutes of Health (NIH) , and National Eye Institute (NEI) .
  • Among the presenters are Dr. Michael F. Chiang, Director, NIH/NEI and Dr. Rohit Varma , Founding Director, Southern California Eye Institute .

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Retrieved on: 
Tuesday, February 7, 2023
Amyotrophic lateral sclerosis, Barrow Neurological Institute, Target, Alpha-synuclein, Disease, Research, Diagnosis, Neurodegeneration, Pathology, The Michael J. Fox Foundation, NDD, MJFF, Frontotemporal lobar degeneration, Precision medicine, International Center, PET, FTLD, Patient, Drug discovery, ALS, Kansas City University, National Center for Research Resources, Senior, AC, TAR, Engineering, Pharmaceutical industry, Medical imaging, Biotechnology

Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Fox Foundation for Parkinson’s Research (MJFF) and Target ALS Foundation (Target ALS) supporting research programs to enable diagnosis of TDP-43 (TAR DNA-binding protein 43), recognized as an important target in multiple neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and as a prominent co-pathology in Alzheimer’s and Parkinson’s diseases.
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “It is an honor to have the support of MJFF and Target ALS, two leading international organizations that recognize the pressing need for diagnostics to detect pathological TDP-43.
  • AC Immune and its collaborators recently demonstrated their expertise in developing cutting-edge PET imaging agents by providing the first images of alpha-synuclein.
  • The development of a TDP-43 specific biofluid-based diagnostic test has the potential to more rapidly enable confirmed early diagnosis.”
    The MJFF and Target ALS grants collectively provide more than USD 500,000 in additional non-dilutive capital to support the advancement of diagnostic programs targeting TDP-43.

CeraVe Establishes Fund at Howard University to Address Lack of Diversity and Increase Representation of Skin of Color in Skincare Clinical Research

Retrieved on: 
Wednesday, November 16, 2022
Advertising, Technology, Pharmacy, Student, Research, Industry, National Institutes of Health, College, Skin, MVE, National, Schwarzman, Howard University, Leadership, Partnership, Howard University Hospital, University, Senior, Medicine, National Center for Research Resources, Department, Marketing, Clinical trial, Engineering, Historically black colleges and universities, Faculty, College of Medicine, S&E, L'Oréal, Population, Human services, School, African Americans, Multimedia, Certification, NIH, Color, Service, Science, Social media, NEW, Group, United States Department of Health and Human Services, Education, Thomas R. Pickering Foreign Affairs Fellowship, UIM, Employment, Contemporary Clinical Trials, Howard University College of Medicine, White, Cosmetics, Pharmaceutical industry, Hospital, Dermatology, Facebook, Black

NEW YORK, Nov. 16, 2022 /PRNewswire/ -- As a brand developed with dermatologists and backed by science, CeraVe is committed to providing safe and efficacious skincare products for all people and recognizes that there are representation gaps within the skincare industry. This includes representation at the clinical research level, both for participants of dermatological clinical trials and the investigators conducting them, of which there is a significant disparity for skin of color. To help close this existing racial inequity gap in dermatological research, CeraVe is establishing a fund at Howard University, one of the only historically Black universities with a Department of Dermatology, to help its faculty further their expertise and build the infrastructure needed to conduct clinical trials with a focus on skin of color.

Key Points: 
  • Diversity is not just lacking in those participating in clinical trials, but also in those conducting the trials.
  • The first stage of the partnership between CeraVe and Howard University, will help fund faculty education to obtain certification to conduct clinical trials.
  • By partnering with the Howard University Dermatology Department, CeraVe is helping the University become a leader in research and innovation of dermatological science for skin of color.
  • Both Howard University and CeraVe are committed to transform values into action to address the health inequities impacting people of color.

Blue Clarity, LLC Announces Crowdsourcing Challenge to Minimize Bias in Healthcare

Retrieved on: 
Tuesday, November 1, 2022
Foundation for the National Institutes of Health, Algorithm, Goal, National Center for Research Resources, Partnership, LLC, Industry, NIH, Bias, Technology, Health care, Strategic management, Decision-making, National Center for Advancing Translational Sciences, Machine learning, History, Artificial intelligence, NCATS, Multimedia, National, Solution, Medical device

Cash prizes for this challenge total $700,000 with several ways to win, including a student prize!

Key Points: 
  • Cash prizes for this challenge total $700,000 with several ways to win, including a student prize!
  • This challenge is open to all U.S.-based companies and U.S. citizens and permanent residents who are over 18 and not Federal employees.
  • However, the AI algorithms themselves must be examined to ensure they are not introducing or perpetuating bias in healthcare decision making.
  • Blue Clarity is owner and operator of the #expeditionhacks hackathon series which brings together socially-conscious developers to build solutions for social impact.

Cameroon and the Mectizan Donation Program sign historic agreement to end neglected tropical diseases

Retrieved on: 
Wednesday, July 20, 2022
Onchocerciasis, Filariasis, NGO, World, Tuberculosis, Population, Center, Research, Tablet, Partnership, Government, Lymphatic filariasis, Merck & Co., Malaria, World Health Organization, Quality of life, LF, Ministry, Merck, SDG, Non-governmental organization, National Center for Research Resources, MDP, Program, United Nations Sustainable Development Group, HIV, Ministry of Public Health (Afghanistan), Public health, Pharmaceutical industry

In the agreement, MDP commits to continuing to make available, free of charge, enough Mectizan for Cameroon's river blindness and LF elimination effort until the World Health Organization declares Cameroon to be free of both diseases.

Key Points: 
  • In the agreement, MDP commits to continuing to make available, free of charge, enough Mectizan for Cameroon's river blindness and LF elimination effort until the World Health Organization declares Cameroon to be free of both diseases.
  • The signing of this agreement is an important step to achieving the elimination targets set by the World Health Organization's Neglected Tropical Diseases Road Map 2021-2030.
  • It will also help to meet the United Nations Sustainable Development Goals (SDG), specifically SDG 3.3to "end the epidemics of HIV, tuberculosis, malaria and neglected tropical diseases" by 2030.
  • The Mectizan Donation Program (MDP) oversees the donation of Mectizan by Merck & Co., Inc., Rahway, New Jersey, USA to eligible countries where river blindness and/or lymphatic filariasis are endemic.